ObsEva
Jul 07, 2020
Regeneron’s cocktail antibody, REGN-COV2; J&J’s manufacturing-spree; ObsEva’s Yselty top-line studies
Regeneron Pharmaceuticals launches the Phase III trials of REGN-COV2 for treatment and prevention of COVID-19. Regeneron is running two trials simultaneously, one for prevention and other for treatment, with the U.S. National Institute of Allergy and Infectious Diseases (NIAID). Phase III trial is studyi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
